DECADRON (dexamethasone sodium phosphate) by Merck & Co. is clinical pharmacology naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Approved for ataxia telangiectasia, peripheral arterial disease, chronic limb ischemia and 3 more indications. First approved in 1959.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
DECADRON (dexamethasone sodium phosphate) is a synthetic glucocorticoid used for its potent anti-inflammatory effects across multiple organ systems. It works by modifying immune responses and metabolic effects while lacking the sodium-retaining properties of natural glucocorticoids. The ophthalmic ointment formulation treats conditions including atopic keratoconjunctivitis and perioperative inflammation.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), teams are likely focused on brand defense and cost management rather than expansion.
CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, including dexamethasone, are primarily used for their potent…
Worked on DECADRON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDECADRON represents a declining-stage commercial opportunity with zero linked job postings, indicating reduced investment in team expansion. Roles available are likely limited to retention and cost management rather than growth initiatives, making this product less attractive for career advancement-focused professionals.